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ABSTRACT 1 
Objective 2 
To investigate a possible association between fever admissions and 4CMenB vaccine 3 
Design 4 
4CMenB is given at 8 and 16 weeks in the first year of life. Self controlled case series using 5 
linked routinely collected healthcare data, where the risk period was the 3 days immediately 6 
following receipt of a vaccine dose.  7 
Patients 8 
Children aged under one year in Scotland pre- and post-introduction of 4CMenB vaccine 9 
Main outcome measures 10 
Hospitalisations for fever attributable to 4CMenB vaccine 11 
Results  12 
The post-introduction model showed an increased risk in the three days after dose 1 (relative 13 
incidence (RI), 10.78; 95% CI, 8.31, 14.00) and dose 3 (RI, 9.80; 95% CI, 7.10, 13.62), with 14 
a smaller increased risk after dose 2 (RI, 2.20; 95% CI, 1.27, 3.82). The magnitude of these 15 
effects was greater than in the pre-introduction model. The attributable fractions were 90.7%, 16 
54.8% and 89.7%, equating to 162, 14 and 84 vaccine attributable cases per 100,000 doses 17 
respectively (Table 2). 18 
This is equivalent to 103 extra hospitalisations in Scotland annually, based on a birth cohort 19 
of 55,100 and extrapolated to 1440 across the UK based on a birth cohort of 777,165. 20 
Conclusion 21 
There is an increased risk of hospital admission with fever within three days of the routine 22 
childhood immunisations at 8 and 16 weeks following introduction of 4CMenB vaccine.  The 23 
results indicate that further understanding of current use of prophylactic paracetamol is 24 
 3 
 
needed and that communication to parents and health professionals may need re-examined 1 
to reinforce guidance. 2 
  3 
 4 
 
INTRODUCTION 1 
Meningococcal disease is a systemic bacterial infection caused by Neisseria meningitidis, an 2 
organism commonly carried harmlessly in the nasopharynx.[1] In the UK, meningococcal 3 
disease serogroup B is responsible for the highest number of cases and remains the main 4 
cause of infant deaths from infectious disease.[2] The disease has a rapid onset and even 5 
with prompt treatment survivors can be left with serious long term sequelae such as 6 
deafness, epilepsy and limb amputations.[3] Vaccination is therefore the most effective 7 
control measure. Although recent years have seen a decline in meningococcal disease 8 
across the UK, new virulent strains can arise resulting in national outbreaks such as MenW, 9 
which prompted introduction of MenACWY vaccine into the adolescent and student 10 
programme.[2,4]  11 
The 4CMenB vaccine, Bexsero® was introduced in Scotland in September 2015 and offered 12 
to all babies born on or after 01 July, 2015 at their routine appointments at 8 weeks, 16 13 
weeks and 12-13 months.[5] There was also an initial catch up programme for babies born 14 
on or after 1 May 2015 and who were attending for vaccinations at 3 and 4 months.  Fever is 15 
a known side-effect when administered alongside other routine vaccines, with highest rates 16 
within 6 hours. Other side-effects such as irritability, drowsiness and loss of appetite were 17 
also reported.[6,7,8]  Results of a clinical trial indicated that administration of prophylactic 18 
paracetamol significantly reduced reports of fever by 40-50% to around the expected 19 
occurrence prior to the introduction of 4CMenB. Reports of other symptoms were also 20 
reduced.[9] As a result, the UK Joint Committee on Vaccination and Immunisation (JCVI) 21 
recommended 3 doses of infant paracetamol following vaccinations at 8 and 16 weeks, with 22 
the first dose given at the time of the vaccination followed by 2 further doses at 4-6 hour 23 
intervals, regardless of whether fever develops.[4]  24 
Suspected Adverse Events Following Immunisation (AEFI) are reported to the UK Medicines 25 
and Healthcare Products Regulatory Agency (MHRA) via the yellow card scheme. We 26 
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developed a supplementary method to proactively identify potential AEFI resulting in hospital 1 
admission. [10] This has been used to monitor rotavirus, shingles, HPV and more recently 2 
4CMenB vaccines. Ongoing monitoring showed a signal for fever admissions corresponding 3 
to the start of the 4CMenB programme. Due to inherent time lags in completion of hospital 4 
admission data, this pattern of repeating signal became more conclusive after a few months. 5 
We therefore decided to investigate, conducting a self-controlled case series analysis 6 
(SCCS), using linked routine healthcare data. This method has previously been used to 7 
investigate potential AEFI, having advantages including control of sex, location, and 8 
underlying health.[11,12,13] 9 
METHODS 10 
Self controlled case series (SCCS) analysis 11 
SMR01 data is held by Information Services Division (ISD) and unit of analysis is an 12 
³HSLVRGH´ An episode is generated when a patient is discharged; transferred between 13 
hospitals or specialties or to a different consultant. Episodes are grouped as continuous 14 
inpatient stays (CIS) and each CIS defined as a case. 15 
Fever cases were extracted from September 2014 until July 2016 for infants using the ICD10 16 
FRGH³5´ and included if recorded in any diagnostic position during the hospital stay. Age 17 
was defined as on admission.  18 
Vaccination records for all children born between January 2013 and August 2016 were 19 
extracted from the Scottish Immunisation & Recall System (SIRS). This study concentrated 20 
on vaccinations given at 8, 12 and 16 weeks. DTaP-IPV-Hib records were examined, to 21 
enable a consistent comparator pre- and post-introduction of 4CMenB. In Scotland, uptake 22 
rates by 12 months of age for complete primary courses of immunisation against DTaP-IPV-23 
Hib are high, with rates around 97%. Uptake of 4CMenB vaccine for the first routine cohort 24 
(born July 2015) was 95.7% for one dose and 82.4% for two doses of vaccine at six months 25 
 6 
 
of age, rising to 94.5% for two doses at age 12 months [14,15]. Table 1 shows the current 1 
routine childhood schedule for infants.  2 
Table 1 Routine childhood immunisation schedule in Scotland (2016) 3 
Age Immunisations 
8 weeks x DTaP/IPV/Hib  
x Pneumococcal (PCV) 
x Rotavirus 
x Meningococcal group B (4CMenB) 
12 weeks  x DTaP/IPV/Hib 
x Rotavirus 
x Meningococcal group C (MenC)* 
16 weeks x DTaP/IPV/Hib 
x Pneumococcal (PCV) 
x Meningococcal group B (4CMenB) 
* MenC was removed from the routine childhood immunisation schedule in September 2016 4 
Vaccination records were matched with fever cases using the Community Health Index (CHI) 5 
number. Fever cases without a CHI number were excluded, which resulted in one case 6 
being excluded. Patients were included whether they had received no, partial or full (three) 7 
doses of DTaP-IPV-Hib. Eight fever cases did not match to SIRS records and were included 8 
as non-vaccinated patients. 9 
Patients were excluded if the time between birth and first dose of DTaP-IPV-Hib was less 10 
than 20 days as assumed to be due to inaccurate recording, resulting in exclusion of 5 fever 11 
cases.  12 
Age in days at time of vaccination and fever admission were calculated and the risk period 13 
defined as 3 days post-DTaP-IPV-Hib vaccination. Figure 1 shows an example of a SCCS 14 
design of a single patient timeline with 2 fever admissions.  15 
The analysis was based on each case of fever, rather than just the first case for each 16 
patient, consistent with the study methodology. The rationale was that the risk after each 17 
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vaccine dose at 8, 12 and 16 weeks would differ due to the differences in vaccination 1 
schedule; therefore each dose was assigned a different risk factor (1, 2 and 3). The 2 
observation period (the rest of the year) was DVVXPHGWRKDYHWKHVDPH³ULVN´DQGWKHUHIRUH3 
coded as 0 (Figure 1). 4 
The data were split into pre- and post-4CMenB vaccine introduction, from September 2014 5 
to August 2015 and September 2015 to June 2016 respectively, and the RIs for each time 6 
period calculated. In the pre-4CMenB vaccination period the RIs are for the DTaP-IPV-Hib 7 
doses while in the post-4CMenB vaccination period for DTaP-IPV-Hib /4CMenB doses. 8 
Comparison of the two sets of RIs demonstrates the impact of the 4CMenB vaccine.  9 
The relative incidence compares the period 3 days after vaccination for an individual to all 10 
days not included in that period for the same individual.  Age was included as a covariate, 11 
taking different values every 30 days.  The analysis was carried out as a conditional logistic 12 
regression, stratified by individual, with covariates of age group and whether or not the 13 
individual was in or out of the exposure period.  The age group effect was used to control 14 
adjust for the different hospitalisation rates in for example, months 0-6 compared to months 15 
6-12, and so the effect of the exposure period takes into account the known differences in 16 
hospitalisation rates associated with age. Age was restricted to those who were under 1 year 17 
at admission. 18 
The case series analysis was carried out in R using the clogit function in the survival 19 
package to account for the repeated observations on the subjects and an offset of the 20 
logarithm of the interval length to account for the exposure period. The attributable fractions 21 
were calculated using the relative incidence (RI-1)/RI x 100 for each risk period of 3 days 22 
after each dose of DTaP-IPV-Hib. This was applied to calculate the attributable number of 23 
cases and a rate calculated using the relevant mid-year population estimates. Confidence 24 
intervals were obtained using a parametric bootstrap approach where the log relative risks 25 
were sampled from a normal distribution and the numbers of cases from Poisson 26 
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distributions, centred at the observed values.  Medians and upper and lower 2.5% 1 
percentiles are reported from the 10,000 bootstrap simulations. 2 
Analysis of admissions for seizures including febrile seizures 3 
SMR01 data was extracted for admissions for all cause seizures including febrile seizures 4 
(R56, G40, G41) within 3 days of the routine child vaccinations at 8, 12 and 16 weeks and 5 
compared pre- and post-vaccine introduction. 6 
Analysis of lumbar puncture procedures 7 
SMR01 data was extracted for admissions which included lumbar puncture procedures (LP) 8 
using OPCS Classification of Interventions and Procedures version (OPCS4) codes 9 
'A553','A558','A559' from  2011 to 2016 within 3 days of the routine child immunisations at 8, 10 
12 and 16 weeks and compared pre- and post-vaccine introduction. 11 
Analysis of Length of Stay 12 
Length of stay was calculated from the extracted SMR01 data within 3 days of the routine 13 
childhood vaccinations at 8, 12 and 16 weeks and compared pre- and post-vaccine 14 
introduction. 15 
Ethics 16 
The investigation received approval from the NHS National Services Scotland Privacy 17 
Advisory Committee. 18 
RESULTS 19 
Self controlled case series analysis 20 
A total of 1435 fever cases were identified; 670 before 4CMenB introduction and 765 21 
following introduction of the programme (Table 2). 22 
Table 2 Number of fever cases pre- and post-4CMenB vaccine introduction 23 
 Pre-4CMenB Post-4CMenB 
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(Sep 2014 to 
Aug 2015) 
(Sep 2015 to 
Jun 2016) 
 
Risk Period  
 
No of cases 
0     (observation) 625   606 
1     (dose1) 27   95 
3     (dose2) 3   14 
5     (dose3) 15  50 
Total  670 765 
 1 
In the pre-introduction model, there was a significantly increased risk in the three days after 2 
both dose 1 and dose 3 (RI, 3.01; 95% CI: 1.99, 4.53, and RI, 2.51; 95% CI: 1.47, 4.27), 3 
(Table 3). The attributable fractions were 66.8% and 60.1% respectively.  Calculation of 4 
vaccine attributable cases, based on an approximate vaccine uptake of 95%, was equivalent 5 
to 33 (95% CI: 20, 49) and 16 (95% CI: 7, 28) cases per 100,000 doses respectively. Dose 2 6 
was not associated with an increased risk of fever admission (RI, 0.43; 95% CI: 0.14, 1.36).  7 
The post-introduction model showed a greater increased risk in the three days after both 8 
dose 1 (RI, 10.78; 95% CI: 8.31, 14.00) and dose 3 (RI, 9.80; 95% CI: 7.10, 13.62) with a 9 
smaller increase risk after dose 2 (RI, 2.20; 95% CI: 1.27, 3.82), compared to the pre-10 
introduction model. The attributable fractions were 90.7%, 54.8% and 89.7%, equivalent to 11 
162 (95% CI: 129, 195), 14 (95% CI: 5, 25) and 84 (95% CI: 62, 109) vaccine attributable 12 
cases per 100,000 doses respectively (Table 3). 13 
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Table 2 Relative incidence of fever admission and attributable cases (per 100,000 vaccinations) in the 3 days following vaccination with DTaP-IPV-
Hib dose pre- and post-introduction of 4CMenB 
 
 
Model 
and dose 
Pre-4CMenB vaccine introduction Post-4CMenB vaccine introduction 
 No of 
events 
RI 
(95% CI) 
Attributable cases per  
100,000 vaccinations 
(95% CI) 
No of 
events 
RI 
(95% CI) 
Attributable cases per 
100,000 vaccinations  
(95% CI) 
Dose 1 27 3.00 (1.99, 4.53) 33 (29, 49)  95 10.78 (8.31, 14.00) 162(129, 195) 
Dose 2 3 0.43 (0.14, 1.36) -6 (-44, 1) 14 2.20  (1.27, 3.83) 14 (5, 25) 
Dose 3 15 2.51 (1.47, 4.27) 16 (7, 28) 50 9.80 (7.06, 13.60) 84 (62, 109) 
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The total number of additional hospitalisations was estimated by comparing attributable 1 
cases before and after the introduction of 4CMenB vaccine. Therefore following dose 1 the 2 
attributable cases would be 128/100,000 (95% CI: 93, 165), which in a birth cohort of 55,100 3 
(Scotland 2015) equivalent to 68 (95% CI: 49, 90) hospitalisations, extrapolated to 940 (95% 4 
CI: 680, 1210) in the UK (UK, 2015). Similarly, for dose 3 the attributable cases would be 67 5 
(95% CI: 43, 94) per 100,000 equating to 35 extra hospitalisations in Scotland (95% CI: 22, 6 
50) and 490 (95% CI: 680, 1210) in the UK. Therefore combining doses 1 and 3 together this 7 
would amount to 103 (95% CI: 80,126) extra hospitalisations in Scotland per year or 1440 8 
(95% CI: 1120, 1770) across the UK.   9 
Seizures including febrile seizures  10 
The proportions of seizure cases within 3 days of the routine childhood immunisations at 8, 11 
12 and 16 weeks were compared pre- and post-vaccine introduction. There were 12/765 12 
(1.57%) cases pre- introduction period (Sep 2013 to August 2015) compared to 8/374 13 
(2.13%) in the post- period (Sep 2015 to August 2016) (P=0.49). 14 
Lumbar punctures 15 
The proportions of LPs within three days of routine childhood immunisations at 8, 12 and 16 16 
weeks were compared pre- and post-vaccine introduction. There were 17/520 (3.27%) in the 17 
pre-introduction period compared to 22/408 in the post-introduction period (5.39%) (p=0.11), 18 
which is not statistically significant. However as the absolute numbers are very low this may 19 
need monitored further.  20 
Length of Stay  21 
Most cases had a short length of stay of either '0' or '1' day. Following 4CMenB introduction, 22 
the increase was observed in short length of stays particularly with the '0' day stays 23 
outnumbering the '1' day stays approx 2:1. Following Dose 1 there were 13/27 (48.1%) of 24 
cases of <1 day length of stay pre-4CMenB introduction compared to 48/95 (50.5%) 25 
 12 
 
(p=0.83). Following dose 3, there were 8/15 (53.3%) cases of <1 day length of stay pre-1 
4CMenB compared to 26/51 (50.9%) post-4CMenB (p=0.87).  2 
 13 
 
DISCUSSION 1 
 2 
This study has demonstrated the usefulness of proactively monitoring hospital admission 3 
data for potential AEFI and the ability to further investigate by linking to vaccination records 4 
using CHI.  5 
The results have shown a significant increased risk of hospital admission with fever within 6 
three days of the routine childhood immunisation schedule at 8 and 16 weeks (dose 1 and 3) 7 
following introduction of 4CMenB.  There was also a small but significant risk following 8 
vaccinations at 12 weeks post-introduction of 4CMenB. This is likely related to the catch-up 9 
campaign at the start of the programme as admissions mainly occurred in the first couple of 10 
months of the programme.[5] The results indicated that markers of severity such as all 11 
convulsions, including febrile, and length of stay were not significantly increased consistent 12 
with clinical trial findings.[8]  13 
To provide context, we estimated the number of additional hospitalisations by comparing 14 
attributable risk pre- and post-introduction of 4CMenB vaccine as equivalent to 103 extra 15 
hospitalisations annually in Scotland and 1,440 across the UK. 16 
Analysis of lumbar puncture procedures was also carried out pre- and post-4CMenB 17 
vaccine. There is currently insufficient evidence that an observed increase is associated with 18 
4CMenB however as the numbers are low this may need monitored further. This is 19 
particularly relevant as current guidance from NICE on management of fever in under 5s 20 
recommends lumbar puncture is carried out on all infants aged 1-3 months with fever who 21 
appear unwell.[16]  22 
An increased risk of fever admissions prior to the introduction of the 4CMenB following 23 
vaccinations at 8 and 16 weeks (dose 1 and 3) was observed. This timing coincides with 24 
pneumococcal conjugate vaccine (PCV) administration. Fever is mentioned as a potential 25 
 14 
 
adverse reaction for PCV with an increased level observed in clinical trials.[17] However the 1 
rates of admission were significantly higher following the introduction of 4CMenB vaccine. 2 
The increased risk of fever associated with 4CMenB vaccine when given along with other 3 
routine vaccinations is a known adverse event.[8] However results of a phase 2 randomised 4 
controlled trial indicated that giving prophylactic paracetamol reduced post-vaccination 5 
reactions including fever down to pre-4CMenB rates, without impacting on 6 
immunogenicity.[9] Therefore the JCVI recommended prophylactic paracetamol at the time 7 
of the vaccinations followed by a further 2 doses.[4,5] Adherence to this recommendation is 8 
not known. It is possible, particularly given the very young age of infants at the time of the 9 
first vaccination, that there may be some reluctance to give paracetamol before a fever is 10 
actually evident, which would reduce its impact. It is therefore unclear if any of these 11 
hospitalisations were avoidable. This is further strengthened by an initial analysis of 12 
community prescribing data from September 2015 until the October 2016 which showed 13 
approximately 1400 prescriptions were written by pharmacists for paracetamol 120mg/5ml 14 
liquid per month in Scotland, as part of a public health service for prophylaxis of post 15 
4CMenB fever.[4,18] This is lower than expected given the high uptake of 4CMenB and size 16 
of the birth cohort (approximately 5000 births per month).  It is not known however if this 17 
represents a real under use of paracetamol or whether parents are not getting prescriptions 18 
as they already hold stocks or purchase elsewhere. Recent studies have shown a rise in 19 
infants presenting to Accident and Emergency departments and consulting with general 20 
practitioners for fever  despite recommendation for prophylactic use of paracetamol.[19,20] 21 
There may also be other factors which led to the increased risk of fever admissions post-22 
introduction, including parental awareness of fever as a known side effect of 4CMenB 23 
vaccine, which we are unable to quantify.  24 
 15 
 
The results indicate that further understanding of current use of prophylactic paracetamol is 1 
needed and that communication to parents and health professionals may need re-examined 2 
to reinforce guidance. 3 
LIMITATIONS 4 
There are a number of limitations to this study. To include as much data as possible in the 5 
post-introduction cohort, we did not limit admissions by date of birth.  Therefore we may not 6 
FDSWXUHHYHU\SDWLHQW¶VILUVWIXOO\HDULHSDWLHQWFRXOGEHERUQLQ)HEDGPLWWHG$SULO7 
2016 and may or may not have had their vaccines. The post-4CMenB model was limited 8 
LQFOXGLQJDIXOO\HDU¶VGDWDGXHWRLQKHUHQWGHOD\LQ60R01 completion at the time of 9 
analysis. In addition, we only looked at fever hospitalisations and were not able to assess 10 
impact on other areas including primary care consultations and attendances at A&E. 11 
Furthermore, we were only able to look at a relatively short period of time following vaccine 12 
introduction. However, none of these should alter the overall result of the study, but rather 13 
increase its power as further data accumulates.  14 
CONCLUSION 15 
There is an increased risk of admission to hospital with fever within three days of the routine 16 
childhood immunisation schedule at 8 and 16 weeks following the introduction of 4CMenB 17 
vaccine.  Other markers for potential severity such as seizures including febrile have not 18 
significantly increased. There is a need for more information on paracetamol use among 19 
parents and care givers. Current communication to parents and health professionals on the 20 
importance of the use of prophylactic paracetamol may also need re-examined.  21 
 22 
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What is already known on this topic 9 
Fever occurs at increased levels following 4CMenB vaccination, leading to 10 
prophylactic paracetamol being recommended for doses at 8 and 16 weeks. 11 
Adherence to this recommendation is not known. 12 
 13 
What this study has added 14 
There are an estimated extra 1,440 hospitalisations for fever associated with 4CMenB 15 
vaccine each year across the UK.  16 
Parents and vaccine providers should be reminded about the importance of following 17 
paracetamol recommendations, not waiting until fever develops. 18 
 19 
 20 
 21 
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